Lepu Hengtong

Lepu (Beijing) Medical Devices Co., Ltd. was founded in 1999, with its headquarters located in Changping Park of Zhongguancun Science Park, Beijing. The company is a high-tech enterprise controlled by central state-owned capital and jointly funded by Chinese and foreign investors, engaged in the research, development, production, and sales of interventional diagnostic and therapeutic medical devices and equipment for cardiovascular diseases, including coronary drug-eluting stents, congenital heart defect occluders, heart valves, and angiography machines. It is one of the first 28 companies listed on the ChiNext board of the Shenzhen Stock Exchange in 2009. The company currently has 8 domestic and overseas subsidiaries, and its products are clinically used in over 1,200 cardiac diagnosis and treatment centers nationwide, having developed into a leading high-end medical product industry group for cardiovascular interventional diagnostic and therapeutic devices and equipment. Lepu brings together professionals in materials, mechanics, electronics, precision processing, and clinical medicine, and has a team with professional and experienced expertise in product development, quality control, clinical validation, market expansion, and corporate management. Its research and development covers high-end interventional products in five major fields: coronary heart disease, structural heart disease, cardiac rhythm, pre- and post-procedural diagnostics, and diagnostic and therapeutic equipment, achieving a series of research results at domestic and international leading levels. It is the largest domestic manufacturer of drug-eluting stents with multiple technical features, the largest artificial heart valve manufacturer in Asia, a pioneer in domestic cardiac pacemakers, a market leader in domestic cardiac occluders and angiography machines, and the first domestic enterprise to develop renal artery radiofrequency ablation catheters. Since its inception, Lepu has undertaken dozens of major national projects, including high-tech industrialization demonstration projects of the National Development and Reform Commission, the 863 Program of the Ministry of Science and Technology, and the Science and Technology Support Program. In 2013, relying on Lepu, the company established the "National Engineering Technology Research Center for Cardiovascular Interventional Diagnostic and Therapeutic Devices and Equipment," which will further promote the construction of a national platform for technological innovation, industrialization, and talent aggregation in this field, overcome core technologies and processes for industry development, and accelerate the rapid progress of China's interventional cardiovascular medical industry. We adhere to the philosophy of "igniting the brilliance of life with the power of technology," providing better and stronger medical products and technologies to healthcare professionals, enabling more cardiovascular patients to access and afford China's own advanced medical technologies and products. Web link: *